COMP <GO>
VMD vs MGRX // ENTERPRISE SCALE & MARKET CAP
Viemed Healthcare Inc. (NASDAQ) VS. Mangoceuticals Inc. (NASDAQ) • 15-METRIC TALLY: VMD 9
— MGRX 0
▲ ENTERPRISE SCALE & MARKET CAP LEADER: VMD
LAST: $9.67 (-2.81%) • MKT CAP: $379.0M
market-cap
$379.0M
LAST: $0.23 (-8.22%) • MKT CAP: $5.7M
market-cap
$5.7M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VMD VS. MGRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VMD | MGRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.50% | 54.90% | +2.60 | VMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.00% | -35.00% | +48.00 | VMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.15% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 8.50% | -60.00% | +68.50 | VMD | /operating-margins <GO> |
| Net Profit Margin | 5.70% | -60.00% | +65.70 | VMD | /net-margins <GO> |
| Revenue Growth (YoY) | 20.50% | -26.00% | +46.50 | VMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.59 | 0.20 | +6.39 | VMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 3/9 | +6.00 | VMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.0 | 36.8 | +23.20 | VMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.7x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $379.0M | $5.7M | $373.3M | VMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VMD REV | MGRX REV | VMD GROSS % | MGRX GROSS % | VMD FCF | MGRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $270.3M | $456.0K | 57.5% | 54.9% | $11.9M | -$5.9M |
| FY 2024 | $224.3M | $615.9K | 59.4% | 61.7% | $1.3M | -$4.9M |
| FY 2023 | $183.0M | $731.5K | — | — | $45.2M | -$7.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VMD // BETA —
MGRX // BETA —